OBJECTIVE: We determined whether there are sex differences in the prevalence and profile of HIV-associated neurocognitive impairment, and whether sex moderates the effect of HIV-serostatus on neurocognitive impairment among HIV-positive and HIV-negative individuals. Secondarily, we assessed whether differences were explained by greater biopsychosocial risk factors in HIV-positive women. DESIGN: An observational cohort study. METHODS: Analyses included 1361 HIV-positive (204 women) and 702 HIV-negative (214 women) (ages = 18-79 years) participants from the UCSD HIV Neurobehavioral Research Program. Demographically corrected standardized T-scores from 15 neuropsychological tests were used to calculate domain-specific and global deficit scores (GDS). GDS at least 0.5 defined neurocognitive impairment. Biopsychosocial risk factors included low education, low reading level (education quality), lifetime substance use disorders, depressed mood (clinically significant depressive symptoms and/or current major depressive disorder) and a cumulative syndemic count (sum of biopsychosocial risk factors, range = 0-4). Race-stratified analyses were conducted. Analyses were adjusted for relevant demographic and clinical factors. RESULTS: HIV-associated neurocognitive impairment was more prevalent in women versus men; however, the difference was eliminated after adjustment for reading level. In sex-stratified logistic regressions, the association between HIV-seropositivity and higher likelihood of neurocognitive impairment was stronger in women versus men; however, the association was attenuated in women, but not men, after adjusting for reading level. These results in the overall sample were specific to blacks. Sex differences in the profile of HIV-associated neurocognitive impairment varied by race. CONCLUSION: Women, particularly black women, were most at-risk for HIV-associated neurocognitive impairment. Higher rates of HIV-associated neurocognitive impairment in women versus men may reflect differences in educational quality.
OBJECTIVE: We determined whether there are sex differences in the prevalence and profile of HIV-associated neurocognitive impairment, and whether sex moderates the effect of HIV-serostatus on neurocognitive impairment among HIV-positive and HIV-negative individuals. Secondarily, we assessed whether differences were explained by greater biopsychosocial risk factors in HIV-positive women. DESIGN: An observational cohort study. METHODS: Analyses included 1361 HIV-positive (204 women) and 702 HIV-negative (214 women) (ages = 18-79 years) participants from the UCSD HIV Neurobehavioral Research Program. Demographically corrected standardized T-scores from 15 neuropsychological tests were used to calculate domain-specific and global deficit scores (GDS). GDS at least 0.5 defined neurocognitive impairment. Biopsychosocial risk factors included low education, low reading level (education quality), lifetime substance use disorders, depressed mood (clinically significant depressive symptoms and/or current major depressive disorder) and a cumulative syndemic count (sum of biopsychosocial risk factors, range = 0-4). Race-stratified analyses were conducted. Analyses were adjusted for relevant demographic and clinical factors. RESULTS:HIV-associated neurocognitive impairment was more prevalent in women versus men; however, the difference was eliminated after adjustment for reading level. In sex-stratified logistic regressions, the association between HIV-seropositivity and higher likelihood of neurocognitive impairment was stronger in women versus men; however, the association was attenuated in women, but not men, after adjusting for reading level. These results in the overall sample were specific to blacks. Sex differences in the profile of HIV-associated neurocognitive impairment varied by race. CONCLUSION:Women, particularly black women, were most at-risk for HIV-associated neurocognitive impairment. Higher rates of HIV-associated neurocognitive impairment in women versus men may reflect differences in educational quality.
Authors: Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2004-05 Impact factor: 2.475
Authors: Knut A Hestad; J Anitha Menon; Mary Silalukey-Ngoma; Donald R Franklin; Mwiya L Imasiku; Kalima Kalima; Robert K Heaton Journal: J Nerv Ment Dis Date: 2012-04 Impact factor: 2.254
Authors: Matthew J Mimiaga; Conall OʼCleirigh; Katie B Biello; Angela M Robertson; Steven A Safren; Thomas J Coates; Beryl A Koblin; Margaret A Chesney; Deborah J Donnell; Ron D Stall; Kenneth H Mayer Journal: J Acquir Immune Defic Syndr Date: 2015-03-01 Impact factor: 3.731
Authors: Leah H Rubin; Judith A Cook; Gayle Springer; Kathleen M Weber; Mardge H Cohen; Eileen M Martin; Victor G Valcour; Lorie Benning; Christine Alden; Joel Milam; Kathryn Anastos; Mary A Young; Deborah R Gustafson; Erin E Sundermann; Pauline M Maki Journal: AIDS Date: 2017-08-28 Impact factor: 4.177
Authors: Ashley M Behrman-Lay; Robert H Paul; Jodi Heaps-Woodruff; Laurie M Baker; Christina Usher; Beau M Ances Journal: J Neurovirol Date: 2015-08-26 Impact factor: 2.643
Authors: Leah H Rubin; Mandakh Bekhbat; Susie Turkson; C Christina Mehta; Pauline M Maki; Kathryn Anastos; Deborah Gustafson; Amanda B Spence; Joel Milam; Felicia C Chow; Kathleen Weber; Gayle Springer; Stephen J Gange; Gretchen N Neigh Journal: Psychosom Med Date: 2022-08-20 Impact factor: 3.864
Authors: Alyssa C Vecchio; Dionna W Williams; Yanxun Xu; Danyang Yu; Deanna Saylor; Sarah Lofgren; Riley O'Toole; David R Boulware; Noeline Nakasujja; Gertrude Nakigozi; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Ned Sacktor; Leah H Rubin Journal: Brain Behav Immun Date: 2020-12-24 Impact factor: 7.217
Authors: Drenna Waldrop; Crista Irwin; W Chance Nicholson; Cheryl A Lee; Allison Webel; Pariya L Fazeli; David E Vance Journal: J Assoc Nurses AIDS Care Date: 2021 May-Jun 01 Impact factor: 1.809
Authors: Rowan Saloner; Erin E Morgan; Mariam A Hussain; David J Moore; Robert K Heaton; Mariana Cherner; Igor Grant; Jennifer E Iudicello Journal: J Neurovirol Date: 2022-01-03 Impact factor: 3.739